- If you are wondering whether Hologic at around US$75.15 is priced for opportunity or already reflects much of the story, the valuation picture is the place to start.
- The stock has been relatively steady in the short term, with a 0.3% decline over the last 7 days and a 0.1% gain over 30 days, while the 1 year return of 22.3% contrasts with modest 3 year and 5 year returns of 4.4% and 4.4%.
- Recent coverage has focused on Hologic as a key medical technology player, with attention on how its portfolio positions it within the healthcare sector and what that might mean for long term demand. This context helps frame why sentiment around the stock and its risk profile may have shifted over the past year.
- Simply Wall St currently gives Hologic a valuation score of 3/6, which suggests some checks indicate potential undervaluation. The next sections will break down those methods, with an even more comprehensive way to think about valuation saved for the end of the article.
Approach 1: Hologic Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It focuses on cash generated for shareholders rather than reported earnings.
Hologic’s latest twelve month free cash flow is about $942.7 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and Simply Wall St projections extend out 10 years, with free cash flow estimates such as $1,014 million in 2026 and $1,144 million in 2028. Beyond the explicit analyst period, the remaining years through 2035 are extrapolated by Simply Wall St to complete the cash flow curve.
Discounting these projected cash flows back to today gives an estimated intrinsic value of $107.91 per share. Compared with the current share price of about $75.15, this implies an intrinsic discount of 30.4%, which indicates Hologic is trading at a notable markdown relative to this cash flow based estimate.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Hologic is undervalued by 30.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Approach 2: Hologic Price vs Earnings
For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It quickly anchors the share price to the business results you see in the income statement.
What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings appear. Higher growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually calls for a lower one.
Hologic currently trades on a P/E of 30.85x. This sits above the Medical Equipment industry average P/E of 27.39x and below the peer group average of 48.74x, so the stock is priced at a premium to the broader industry but not to higher rated peers.
Simply Wall St’s Fair Ratio is a proprietary estimate of what Hologic’s P/E might be, given its earnings growth profile, industry, profit margins, market cap and risk factors. This Fair Ratio of 30.81x is designed to be more tailored than a simple comparison with industry or peer averages because it adjusts for the company’s own fundamentals rather than assuming all peers deserve similar pricing.
Compared with the current P/E of 30.85x, the Fair Ratio of 30.81x is very close, which suggests the market price is broadly in line with this earnings based assessment.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Hologic Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Hologic to the numbers by linking your view on its future revenue, earnings and margins to a financial forecast, a Fair Value, and then an explicit comparison of that Fair Value with the current price. All of this is available within an easy tool on the Community page that updates automatically as news or earnings arrive and can reflect very different perspectives. For example, one investor might focus on the higher end analyst fair value of around US$94.00 based on stronger execution, while another might anchor closer to the US$65.00 low case because of concerns around international headwinds and the pending buyout at up to US$79 per share.
Do you think there's more to the story for Hologic? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com